474 — Aceso Life Science Income Statement
0.000.00%
Last trade - 00:00- HK$140.26m
- HK$2.41bn
- HK$195.00m
Annual income statement for Aceso Life Science, fiscal year end - March 31st, HKD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | HKAS | HKAS | HKAS | HKAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 346 | 315 | 312 | 228 | 195 |
| Cost of Revenue | |||||
| Gross Profit | 213 | 162 | 141 | 117 | 90 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 770 | 637 | 187 | 585 | 1,003 |
| Operating Profit | -424 | -322 | 125 | -357 | -808 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -323 | -555 | -213 | -823 | -1,027 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -348 | -596 | -208 | -809 | -1,017 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -376 | -370 | -264 | -462 | -895 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -376 | -370 | -264 | -462 | -895 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.019 | -0.053 | -0.046 | -0.057 | -0.096 |